SCHEDULE 13G/A: Perceptive Advisors and Affiliates Disclose 4.8% Passive Stake in Praxis Precision Medicines
Beneficial Ownership Report
Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have jointly reported beneficial ownership of 4.8% of Praxis Precision Medicines, Inc.'s common stock in an amended Schedule 13G filing.
Summary
- Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. (collectively, the "Reporting Persons") have filed an Amendment No. 2 to Schedule 13G regarding their beneficial ownership in Praxis Precision Medicines, Inc.
- As of March 31, 2025, the Reporting Persons collectively beneficially own 980,894 shares of Praxis Precision Medicines, Inc. Common Stock.
- This ownership represents 4.8% of the Issuer's outstanding Common Stock.
- The percentage is calculated based on 20,368,982 shares of Common Stock outstanding as of April 30, 2025, as reported by the Issuer in its Quarterly Report on Form 10-Q filed on May 2, 2025.
- Perceptive Life Sciences Master Fund, Ltd. directly holds all 980,894 shares.
- Perceptive Advisors LLC serves as the investment manager to the Master Fund, and Joseph Edelman is the managing member of Perceptive Advisors LLC, leading to shared voting and dispositive power over the shares.
- The filing certifies that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: This filing is a standard beneficial ownership disclosure and does not contain information that would indicate a positive or negative sentiment regarding the issuer's performance or outlook. It is a factual report of an investment stake.
Future Outlook
This Schedule 13G filing is a disclosure of beneficial ownership and does not contain any forward-looking statements or guidance regarding the issuer's future performance or outlook.
Industry Context
This filing is a standard regulatory disclosure of a passive investment stake by an investment firm in a publicly traded biotechnology company. It does not provide specific insights into broader industry trends or competitive landscape beyond the fact of the investment itself.
Stakeholder Impact
- Shareholders: The disclosure of a passive stake by a notable investment firm like Perceptive Advisors may be viewed as a neutral to slightly positive signal, indicating institutional interest in the company, although the stake is below the 5% threshold.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which required the filing of this statement, indicating the beneficial ownership percentage as of this date. |
| 04/30/2025 | Date as of which 20,368,982 shares of Common Stock were reported outstanding by the Issuer. |
| 05/02/2025 | Date the Issuer's Quarterly Report on Form 10-Q was filed, providing the shares outstanding figure. |
| 05/15/2025 | Date the Schedule 13G Amendment No. 2 was signed and filed. |
Keywords
Praxis Precision Medicines, Perceptive Advisors, Joseph Edelman, Perceptive Life Sciences Master Fund, Schedule 13G, beneficial ownership, common stock, investment, biotechnology, pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.